Merck KGaA bets on RNAi with $1.3B Silence buyout
Summary:
Merck KGaA has agreed to buy UK RNAi specialist Silence Therapeutics for about $1.3 billion, or $20 in cash per US-listed share, a 130% premium. The deal centres on divesiran, an siRNA that produced positive Phase 2 data in the rare blood disorder polycythaemia vera. Completion is expected in the first quarter of 2027.
Roche expands Hansoh ADC partnership with over $15B in potential milestones
Summary:
Roche will pay Hansoh Pharma $400m upfront and $110m on the first anniversary, with more than $15bn in potential milestones plus royalties. The collaboration covers two preclinical ADCs and additional programmes against Roche-proposed targets. Neither the drugs nor the diseases were disclosed. It is Roche’s sixth China deal since late August.
Lilly allies with METiS in $1.1B AI nanoparticle discovery deal
Summary:
Eli Lilly has partnered with Hong Kong-listed METiS TechBio to use its AI-driven ionisable-lipid platform to design tissue-specific lipid nanoparticle delivery systems for programmes Lilly selects. METiS receives an upfront payment in the low double-digit millions of dollars, up to about $1.1 billion in milestones, and tiered single-digit royalties.
FDA approves immunotherapy that may spare rectal cancer patients chemotherapy, radiation and surgery
Summary:
The FDA granted accelerated approval to GSK’s Jemperli (dostarlimab) as the sole treatment for previously untreated stage II–III mismatch repair-deficient or MSI-high locally advanced rectal cancer. In the Phase 2 AZUR-1 trial of 154 patients, almost three-quarters needed no surgery, radiotherapy or chemotherapy after a median follow-up of more than two years.
FDA launches Rare Disease Framework Initiative
Summary:
The FDA is developing a framework to tailor evidence requirements to individual rare diseases and small patient populations while maintaining safety and effectiveness standards. Its scope spans pre-IND engagement through post-approval obligations. A public meeting is scheduled for 28 October 2026; only about 5% of rare conditions have an FDA-approved treatment.
